Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H20Cl2N2OS.HNO3 |
Molecular Weight | 518.412 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.ClC1=CC=C(C(CN2C=CN=C2)OCC3=CC=C(SC4=CC=CC=C4)C=C3)C(Cl)=C1
InChI
InChIKey=FJNRUWDGCVDXLU-UHFFFAOYSA-N
InChI=1S/C24H20Cl2N2OS.HNO3/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20;2-1(3)4/h1-14,17,24H,15-16H2;(H,2,3,4)
Molecular Formula | HNO3 |
Molecular Weight | 63.0128 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H20Cl2N2OS |
Molecular Weight | 455.399 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Fenticonazole is an imidazole derivative with a broad spectrum of antimycotic activity. It is used as a nitrate salt under different trade names (Lomexin, Gynoxin, Fentizol, etc) for the treatment of vaginal candidiasis. Fenticonazole inhibits the synthesis of ergosterol, an important step in the formation of the wall of fungi and blocks the oxidizing enzymes with the corresponding accumulation of peroxides and necrosis of the fungal cell. In vitro studies have shown a broad fungistatic and fungicidal activity. Like other azole agents, the spectrum of action of Fenticonazole also extends to some gram-positive bacteria such as Staphylococcus aureus. In vivo studies have also shown activity against Trichomonas Vaginalis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1780 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25204341 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | LOMEXIN Approved UseLomexin is used to treat a common vaginal infection known as vaginal candidiasis (vaginal thrush) in adolescents more than 16 years and adults. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.499 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, topical dose: 0.1 g route of administration: Topical experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.957 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, vaginal dose: 0.1 g route of administration: Vaginal experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.914 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, topical dose: 0.1 g route of administration: Topical experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
159.22 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, vaginal dose: 0.1 g route of administration: Vaginal experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.883 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, topical dose: 0.1 g route of administration: Topical experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
26.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29404019/ |
0.1 g single, vaginal dose: 0.1 g route of administration: Vaginal experiment type: SINGLE co-administered: |
FENTICONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day multiple, vaginal Studied dose Dose: 5 g, 1 times / day Route: vaginal Route: multiple Dose: 5 g, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
200 mg 1 times / day multiple, vaginal Studied dose Dose: 200 mg, 1 times / day Route: vaginal Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
600 mg single, vaginal Studied dose Dose: 600 mg Route: vaginal Route: single Dose: 600 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
1000 mg single, vaginal Highest studied dose Dose: 1000 mg Route: vaginal Route: single Dose: 1000 mg Sources: |
unhealthy |
PubMed
Title | Date | PubMed |
---|---|---|
Irritation and toxicity studies with fenticonazole applied topically to the skin and mucous membranes. | 1981 |
|
In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp. | 1992 Apr |
Patents
Sample Use Guides
The recommended dose is 1 soft vaginal capsule of 200 mg for three consecutive days or 1 soft vaginal capsule of 600 mg (single administration).
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19223627
Candida strains were treated with fenticonazole at a final concentration range of 0.0312 ug/ml to 32 ug/ml. MIC50 values were 0.03-0.5 ug/ml for C. albicans, 0.03-1 ug/ml for C. glabrata, 0.03-1 ug/ml for C. parapsilosis and 0.06-2 ug/ml for C. krusei.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:15 GMT 2025
by
admin
on
Mon Mar 31 18:00:15 GMT 2025
|
Record UNII |
8V4JGC8YRF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5302
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | Merck Index | ||
|
277-302-6
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
83606
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
DTXSID30993890
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
73151-29-8
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
SUB13831MIG
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
8V4JGC8YRF
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
100000091096
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
236229
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | RxNorm | ||
|
C81508
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL1651990
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY | |||
|
51754
Created by
admin on Mon Mar 31 18:00:15 GMT 2025 , Edited by admin on Mon Mar 31 18:00:15 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |